Strategic partnerships Target collaborations with CF foundations and respiratory disease consortia leveraging ReCode’s inhaled mRNA delivery and SORT LNP platform to accelerate pulmonary therapies and expand into cystic fibrosis and related airway disorders.

Clinical momentum Capitalize on ongoing and upcoming trials (e.g., RCT1100 PCD program and RCT2100 for CF) to engage biopharma partners interested in infectious and genetic lung disease pipelines, offering co-development or licensing of delivery technology.

Financing signals Leverage recent funding rounds and philanthropic investments to approach venture and strategic investors for joint ventures, milestone-based partnerships, or royalty-backed collaborations around the SORT LNP platform.

Platform expansion Highlight the potential to license or co-develop additional delivery targets beyond the liver, enabling partners to pursue systemic and organ-specific therapies, broadening applicability to gene editing and mRNA programs.

Employer credibility Use recognition as Best Place to Work and collaborative ties with NYMC and CF foundations to approach potential customers and service clients who value strong execution, clinical expertise, and reputable partnerships in genetic medicines.